Inovio Publishes Patient Benefit Results From A Pilot Clinical...
PLYMOUTH MEETING, Pennsylvania, Feb. 4, 2020 /PRNewswire-AsiaNet/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced publication of data from its pilot clinical study of INO-3106, a novel DNA therapy targeting human papilloma virus type 6 (HPV 6) for the treatment of recurrent respiratory papillomatosis ...
Authors: LATEST ASIANET NEWS RELEASES